Literature DB >> 4696737

Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease.

F Dreyfuss, J Zahavi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4696737     DOI: 10.1016/0021-9150(73)90139-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  11 in total

1.  Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort.

Authors:  P C Elwood; S Renaud; A D Beswick; J R O'Brien; P M Sweetnam
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

2.  A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.

Authors:  M M Kubik; S G Richardson
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

3.  Platelet-release reaction in myocardial infarction.

Authors:  S Heptinstall; G P Mulley; P M Taylor; J R Mitchell
Journal:  Br Med J       Date:  1980-01-12

4.  Influence of vasodilators used in the therapy of heart failure on platelet aggregation.

Authors:  B Pfister; P Imhof
Journal:  Agents Actions       Date:  1979-06

5.  Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.

Authors:  J De Crée; V Roels; H Verhaegen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Inhibition of adrenaline-induced platelet aggregation by the orally administered alpha-adrenergic receptor blocker phentolamine (Regitine).

Authors:  B Pfister; P R Imhof
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

7.  Effects of leukotrienes C4 and D4 on human isolated saphenous veins.

Authors:  S P Allen; A H Chester; P J Piper; A P Sampson; E S Akl; M H Yacoub
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

8.  The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

Authors:  J De Cree; J Leempoels; B Demoen; V Roels; H Verhaegen
Journal:  Agents Actions       Date:  1985-07

Review 9.  Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.

Authors:  F De Clerck; J M van Nueten; R S Reneman
Journal:  Agents Actions       Date:  1984-12

10.  Platelets, aspirin and cardiovascular disease.

Authors:  P C Elwood
Journal:  J R Coll Physicians Lond       Date:  1976-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.